In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

In­cyte’s stal­wart JAK in­hibitor Jakafi has raced out to block­buster sales with­out the safe­ty bur­den of oth­er drugs in the class. Now, the drug­mak­er’s quest to re­for­mu­late the drug for eas­i­er use could be near­ing fruition — but big chal­lengers await.

The FDA will give a pri­or­i­ty re­view to In­cyte’s top­i­cal cream re­for­mu­la­tion of JAK in­hibitor Jakafi in atopic der­mati­tis, the drug­mak­er an­nounced Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER